Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 11/2007

01-11-2007 | Case Report

Limited Wegener’s granulomatosis—is it limited?

Authors: Svetlana Lisitsin, Raymond Farah, Moshe Shay

Published in: Clinical Rheumatology | Issue 11/2007

Login to get access

Abstract

Complete heart block associated with Wegener’s granulomatosis (WG) is rare especially in the limited form of the disease. We describe a case of a 43-year-old woman with a limited form of WG who developed a complete heart block. Prompt treatment with steroids and cyclophosphamide led to temporary regression of complete heart block. Further involvement of lung was treated successfully by tumor necrosis factor-alpha inhibitor infliximab. Cardiac rhythm abnormalities should always be kept in mind both in diagnosis and follow-up of WG.
Literature
1.
Luqmani RA, Bacon PA, Beaman M et al (1994) Classical versus non-renal Wegener’s granulomatosis. Q J Med 87(3):161–167PubMed
2.
Ahmad I, Lee WC, Nagendran V, Wilson F, Shortridge RT (2000) Localised Wegener’s granulomatosis in otolaryngology: a review of six cases. ORL J Otorhinolaryngol Relat Spec 62(3):149–155PubMed
3.
Hansen LS, Silverman S Jr, Pons VG et al (1985) Limited Wegener’s granulomatosis. Report of case with oral, renal and skin involvement. Oral Surg Oral Med Oral Pathol 60(5):524–531PubMedCrossRef
4.
5.
Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMed
6.
Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed
7.
Pinching AJ, Lockwood CM, Pussell BA et al (1983) Wegener’s granulomatosis: observation on 18 patients with severe renal disease. Q J Med 208:435–460
8.
Forstot JZ, Overlie PA, Neufeld GK, Harmon CE, Forstot SL (1980) Cardiac complications of Wegener’s granulomatosis: a case report of complete heart block and review of literature. Semin Arthritis Rheum 10:148–154PubMedCrossRef
9.
Handa R, Wali JP, Aggarwal P, Wig N, Biswas A, Kumar AK (1997) Wegener’s granulomatosis with complete heart block. Clin Exp Rheumatol 15:97–99PubMed
10.
Wilcke JT, Nielsen PK, Jacobsen TN (2003) Reversible complete heart block due to Wegener’s granulomatosis. Int J Cardiol 89:297–298PubMed
11.
Suleymenlar G, Sarikaya M, Sari R, Tuncer M, Sevinc A (2002) Complete heart block in a patient with Wegener’s granulomatosis in remission—a case report. Angiology 53(3):337–340PubMedCrossRef
12.
Ghaussy NO, Du Clos TW, Ashley PA (2004) Limited Wegener’s granulomatosis presenting with complete heart block. Scand J Rheumatol 33:115–118PubMedCrossRef
13.
Lamprecht P, Voswinkel J, Lilienthal B et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41:1303–1307CrossRef
14.
Kleinert J, Lorenz M, Kostler W, Horl W, Sunder-Plassmann G, Soleiman A (2004) Refractory Wegener’s granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 116(9–10):334–338PubMedCrossRef
15.
Bartolucci P, Ramanoelina J, Cohen P et al (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41(10):1126–1132CrossRef
Metadata
Title
Limited Wegener’s granulomatosis—is it limited?
Authors
Svetlana Lisitsin
Raymond Farah
Moshe Shay
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 11/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0612-3

Other articles of this Issue 11/2007

Clinical Rheumatology 11/2007 Go to the issue

Case Report

Immunological diagnosis of cutaneous-pulmonary hypersensitivity vasculitis

Editorial

The international classification for functioning, disability and health

Case Report

A case of silent giant cell arteritis involving the entire aorta, carotid artery and brachial artery screened by integrated PET/CT

Book Review

Michael H. Weisman, John D. Reveille, Desiree van der Heijde: Ankylosing spondylitis and the spondylarthropaties: a companion to rheumatology, 3rd edn

Case Report

Spontaneous multiple insufficiency fractures after pelvic abscess and sepsis in a rheumatoid arthritis patient treated with high-load corticosteroid therapy: a case report

Case Report

B-flow ultrasound in a case of giant cell arteritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits